March 5 (Reuters) - The U.S. Food and Drug Administration has cleared the use of Dexcom's device making it the first continuous glucose monitor to be available over the counter, the health regulator said on Tuesday. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.3 USD | -9.91% | -4.87% | +0.20% |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
Apr. 26 | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.20% | 49.45B | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.36% | 26.25B | |
+2.07% | 26.48B | |
+12.96% | 24.62B | |
-1.93% | 24.52B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- US FDA clears use of first over-the-counter continuous glucose monitor